C07K 14/8125
Alpha-1-antitrypsin
Official title: {Alpha-1-antitrypsin}
C07K14/8125 (Alpha-1-antitrypsin) appears on 234 US grants and 305 published applications in this corpus.
Search patents in C07K- Granted patents
- 234
- Published applications
- 305
- Assignees
- 171
- Inventors
- 529
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 9 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 8 | 0 |
| 2001 | 5 | 0 |
| 2002 | 2 | 7 |
| 2003 | 2 | 9 |
| 2004 | 2 | 9 |
| 2005 | 1 | 4 |
| 2006 | 8 | 3 |
| 2007 | 5 | 6 |
| 2008 | 3 | 10 |
| 2009 | 1 | 5 |
| 2010 | 6 | 11 |
| 2011 | 3 | 9 |
| 2012 | 6 | 9 |
| 2013 | 4 | 10 |
| 2014 | 9 | 26 |
| 2015 | 10 | 17 |
| 2016 | 17 | 12 |
| 2017 | 12 | 20 |
| 2018 | 12 | 16 |
| 2019 | 13 | 11 |
| 2020 | 12 | 23 |
| 2021 | 8 | 17 |
| 2022 | 7 | 20 |
| 2023 | 5 | 15 |
| 2024 | 10 | 11 |
| 2025 | 8 | 14 |
| 2026 | 3 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vectors encoding a glucose-6-phosphatase (G6PASE-A) for gene therapy1 Sep 2026US 12,723,263 B2Genethon
- RAAV-based compositions and methods19 May 2026US 12,630,824 B2University of Massachusetts
- Compositions and methods for treating alpha-1 antitrypsin deficiency12 May 2026US 12,622,931 B2Beam Therapeutics Inc.
- Compositions and methods for linear and conformational site-specific antibodies and methods of making the same30 Dec 2025US 12,509,508 B2Abbratech, Inc.
- Compositions and methods for alpha-1-antitrypsin disorders16 Dec 2025US 12,497,441 B2Spin Therapeutics, LLC
- Compositions and methods for prevention and treatment of genetic disease20 Aug 2026US 2026/0240889 A1Children's Medical Center Corporation
- Protein complex and production process thereof6 Aug 2026US 2026/0226418 A1Darwin Biotechnology (Hubei) Co., Ltd.
- Chemically modified antisense oligonucleotides (asos) and compositions for rna editing25 Jun 2026US 2026/0176632 A1AIRNA Corporation
- Compositions and methods for treating alpha-1 antitrypsin deficiency7 May 2026US 2026/0125690 A1Intellia Therapeutics, Inc.
- Compositions and methods for alpha-1-antitrypsin disorders2 Apr 2026US 2026/0092099 A1Spin Therapeutics, LLC
Most cited
By later US patents
- Pericardial delivery of therapeutic and diagnostic agents189US 5,797,870 AIndiana University Foundation · 1998
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same124US 6,759,237 B1The Trustees of the University of Pennsylvania · 2004
- Eukaryotic regulatable transcription111US 4,876,197 AChiron Corporation · 1989
- Eukaryotic regulatable transcription110US 4,880,734 AChiron Corporation · 1989
- Glycolytic promotersfor regulated protein expression: protease inhibitor99US 4,599,311 A1986